Pro Perks

We’ve curated a suite of tools and services designed to support biopharma communicators in their unique roles. T2B Pro members gain preferred pricing and insider access to programs vetted specifically for our industry’s needs – because the right resources can make all the difference.

Image Description

T2B picks

We’ve personally researched and reviewed this set of platforms that have value for everyday biopharma comms use cases. To help make these tools more accessible, our partners offer special discounts to T2B Pro members.

PartnerProgram Summary
FullIntel
Customized AI Monitoring Hub for Biopharma Communicators		T2B has partnered with award-winning monitoring firm FullIntel to develop a specialized monitoring solution specifically for biopharma communicators. Out of the box for T2B Pro members, you can easily curate your alerts to include updates on peers and competitors, therapeutic area developments, MOA advancements, relevant medical and scientific meetings, and more. With the $2,500 entry point for a year of alerts, this offering is accessible for all members of our community, from freelancers to larger agencies and comms teams.Learn more
Finvisor
Accounting, Payroll, and CFO Fractional Support		T2B has teamed up with fellow small business Finvisor for a steep discount of 50% off three months of service (six months minimum contract) for any kind of finance-related support you may need. T2B members who are independent practitioners or run small firms will especially appreciate Finvisor's flexible and affordable pricing models that can easily scale up or down depending on your needs. From bookkeeping to people ops, Finvisor has got you covered so you can step away from those spreadsheets and back to communicating!Learn more

Real-time Slack access to MM+M

Pro members gain exclusive real-time access to Jameson Fleming, editor-in-chief of MM+M, through a dedicated private Slack channel. Engage directly with Jameson to discuss industry topics, respond to his calls for sources, or even DM him privately to pitch ideas—a novel opportunity to build a stronger relationship with this stalwart trade publication.

“MM+M wants to cultivate closer connections with the mar-comm decision makers who are often the front door into the brand. I hope this leads to more vibrant storytelling by MM+M about the topics and issues the pharma industry wants to read more about.” -Jameson Fleming